GET DAILY SIGNALSStereotaxis (STXS) Q3 2026 Earnings Preview: Tracking the Shift to New Products
Key Takeaways
- Stereotaxis is scheduled to report its third quarter 2026 results after the U.S. market close on Tuesday, November 10, 2026.
- Consensus estimates point to a net loss of roughly $0.05 per share on revenue near $9.6 million.
- Management has guided to about $7 million in recurring revenue and $3 million in system revenue for the quarter.
- The company is navigating a commercial transition, ramping its MAGiC catheter and GenesisX robot while winding down its legacy Johnson & Johnson relationship.
- Robotic catheter revenue surpassed $1 million in Q2 2026, up 270% sequentially, making it a critical metric for this report.
- Investors will watch whether accelerating catheter adoption can offset softer capital-equipment (system) sales.
- For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Looking for automated trade ideas? Explore Trending AI Robots to see AI-driven strategies in action.
Earnings Context and Its Significance
Stereotaxis develops robotic systems for minimally invasive endovascular procedures, mainly in cardiac electrophysiology for treating heart rhythm disorders. This quarter stands out because the company sits at an early stage of a multi-year product transition. After the U.S. FDA approval of its MAGiC cardiac ablation catheter in January 2026 and clearance of the Synchrony digital operating room system in April, Stereotaxis completed its acquisition of Robocath in July. The Q3 results will indicate whether these newer offerings are driving sustainable revenue growth, which ties directly into the company’s target of achieving cash-flow profitability in the first half of 2027.
What Analysts Expect
Analysts project a net loss of about $0.05 per share for the third quarter of 2026, similar to the prior quarter. Revenue estimates sit near $9.6 million, which would represent solid year-over-year growth from the $7.46 million posted in Q3 2025. Management guidance suggests total revenue around $10 million, split between roughly $7 million in recurring revenue and $3 million in system revenue.
These numbers deserve attention because recent results have varied. In Q2 2026, revenue reached $7.67 million, down 12% from a year earlier due to fewer robotic system deliveries. EPS came in at a loss of $0.05 per share. The upcoming release should clarify whether the expanding product lineup is starting to make up for the decline in legacy third-party catheter sales.
Market Reaction and Sentiment
Investor sentiment ahead of the report mixes optimism around regulatory progress with caution on execution. The stock has reacted to revenue trends in the past, and Q2 2026 drew a modest negative response after missing consensus. Potential concerns include production limits on the MAGiC catheter, where demand has outpaced supply, and the ongoing effects of the Johnson & Johnson transition on recurring revenue. The market will likely focus on whether recurring revenue and catheter momentum support the broader growth story.
Forward Outlook and Metrics to Follow
Several elements beyond the headline numbers will influence how investors view Stereotaxis in coming quarters. The speed of MAGiC catheter adoption remains the top focus. Management expects contract manufacturing to exceed 500 catheters per month by year-end, so any updates on supply expansion will stand out.
Capital equipment sales also matter. The GenesisX robotic system, designed for installation in existing catheterization labs without major construction, aims to revive system revenue. Early orders and installations of the Synchrony system should add to results as well. Tracking order backlog and installation commentary will help gauge lasting demand for these platforms.
The path to cash-flow profitability stays central. Management has targeted the first half of 2027 for reaching that milestone, helped by growing recurring revenue. Updates on gross margins, operating expense control, and cash levels will show whether the timeline holds without needing extra financing.
Integrating AI Tools Into My Analysis
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. These kinds of tools help surface relevant patterns and benchmarks that complement traditional fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STXS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for STXS turned positive on November 05, 2026. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on STXS as a result. In 90 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +8.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 152 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for STXS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.921) is normal, around the industry mean (4.964). P/E Ratio (-4.542) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a designer of robotic cardiology instrument navigation systems
Industry PharmaceuticalsOther
Advertisement